Abstract:Background: Acute myelogenous leukemia (AML) is nosocomial with the highest pediatric mortality rates and a relatively poor prognosis. C4.4A ( LYPD3 ) is a tumorigenic and high-glycosylated cell surface protein that has been proven to be linked with the carcinogenic effects in solid tumors, but no hematologic tumors have been reported. We focus on exploring the molecular mechanism of LYPD3 in the regulation of the occurrence and development of AML to provide a research basis for the screening of markers related to the treatment and prognosis. Methods: Datasets on RNA Sequencing (RNA-seq) and mRNA expression profiles of 510 samples were obtained from The Cancer Genome Atlas Program/The Genotype-Tissue Expression (Tcga-gtex) on 10 March 2021, which included the information on 173 AML tumorous tissue samples and 337 normal blood samples. The differential expression, identification of prognostic genes based on the COX regression model, and LASSO regression were analyzed. In order to better verify, experiments including gene knockdown mediated by small interfering RNA (siRNA), cell proliferation assays, and Western blot were prefomed. We studied the possible associated pathways through which LYPD3 may have an impact on the pathogenesis and prognosis of AML by gene set enrichment analysis (GSEA). Results: A total of 11,490 differential expression genes (DEGs) were identified. Among them, 4,164 genes were upregulated, and 7,756 genes were downregulated. The univariate Cox regression analysis and LASSO regression analysis found that 28 genes including LYPD3 , DNAJC8 , and other genes were associated with overall survival (OS). After multivariate Cox analysis, a total of 10 genes were considered significantly correlated with OS in AML including LYPD3 , which had a poor impact on AML ( p <0.05). The experiment results also supported the above conclusion. We identified 25 pathways, including the E2F signaling pathway, p53 signaling pathway, and PI3K_AKT signaling pathway, that were significantly upregulated in AML samples with high LYPD3 expression ( p < 0.05) by GSEA. Further, the results of the experiment suggested that LYPD3 participates in the development of AML through the p53 signaling pathway or/and PI3K/AKT signaling pathway. Conclusion: This study first proved that the expression of LYPD3 was elevated in AML, which was correlated with poor clinical characteristics and prognosis. In addition, LYPD3 participates in the development of AML through p53 or/and the PI3K/AKT signaling pathway.

ADCY7 Supports Development of Acute Myeloid Leukemia

Low Expression of ACLY Associates with Favorable Prognosis in Acute Myeloid Leukemia

Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis.

Identification of TET1⊣miR-22⊣CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway.

Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199

Adhesion GPCR ADGRE2 Maintains Proteostasis to Promote Progression in Acute Myeloid Leukemia

Acer3 Supports Development of Acute Myeloid Leukemia

Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1

ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/β-catenin signaling by palmitoylation modification

Integrated analysis and validation reveal CYTH4 as a potential prognostic biomarker in acute myeloid leukemia

circSLC25A13 acts as a ceRNA to regulate AML progression via miR‐616‐3p/ADCY2 axis

ADAM28 Promotes Tumor Growth and Dissemination of Acute Myeloid Leukemia Through IGFBP-3 Degradation and IGF-I-induced Cell Proliferation.

A Pan-Cancer Analysis of the Prognostic Value and Expression of Adenylate Cyclase 7 (ADCY7) in Human Tumors

Therapeutic Inhibition of GAS6-AS1/YBX1/MYC Axis Suppresses Cell Propagation and Disease Progression of Acute Myeloid Leukemia

Discovery of a selective YTHDC1 inhibitor that targets acute myeloid leukemia

ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia

C-Myc Plays a Critical Role in the Antileukemic Activity of the Mcl-1-selective Inhibitor AZD5991 in Acute Myeloid Leukemia

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating C-Myc.

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia